Purchase this article with an account.
B.F. Hogewind, K.F. W. Vandoninck, J.E. Keunen, C.B. Hoyng; Somatostatin in Dominant Cystoid Macula Dystrophy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):547.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Dominant Cystoid Macula Dystrophy (DCMD) is an autosomal dominant retinal dystrophy defined by leaking capillaries; especially perimacularly. Since somatostatine analogues like octreotide have a suggested positive effect in macular edema, we hypothesized that somatostatin could also have an positive effect on the early stages of DCMD. Methods: In this prospective study fluoresceine angiography (FAG) and vision acuity were assessed of 10 proven DCMD patients. OCT was performed in 2 patients and ERG/EOG in 3 patients. Each patient received 10 mg somatostatin IM once every six weeks. After 4 and 8 months we repeated the FAG, the vision examination and we measured eventual subjective decline or improvement. Results: At 8 months after treatment, all patients showed clear remission of the the edema on the FAG and on the OCT. 1 Patient showed significant improvement of vision, the other 9 did not show any significant changes. 8 Patients claimed subjective improvement, 2 patients did not experience any visual changes. Conclusions: The results show clear remission of the edema in DCMD, though there is no significant vision improvement. This study shows that somatostatin has a positive effect in the pathogenesis of DCMD, but more research needs to be done to analyse if vision decrease can be stabilized in the long run of the disease.
This PDF is available to Subscribers Only